<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525769</url>
  </required_header>
  <id_info>
    <org_study_id>007</org_study_id>
    <nct_id>NCT03525769</nct_id>
  </id_info>
  <brief_title>Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes</brief_title>
  <official_title>Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes：A Registry and Diagnostic Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed at calculating the incidence of nonalcoholic fatty liver disease (NAFLD),&#xD;
      non- alcoholic steatohepatitis (NASH) cirrhosis and advanced fibrosis in patients with type 2&#xD;
      diabetes in China, evaluating the diagnostic efficacy of FibroTouch for hepatic steatosis and&#xD;
      fibrosis in these patients, analyzing the long-term prognosis and screening potential risk&#xD;
      factors in patients with both type 2 diabetes and NAFLD.&#xD;
&#xD;
      This study will use FibroTouch to screen NAFLD, NASH cirrhosis and advanced fibrosis in&#xD;
      patients with type 2 diabetes, compare the results with liver tissue biopsy to assess the&#xD;
      clinical value of FibroTouch for the screening of NAFLD in diabetics, then investigate the&#xD;
      clinical significance of FibroTouch in assessing the long-term prognosis of patients with&#xD;
      diabetes and NAFLD in a prospective cohort, screen risk factors for diabetes with NAFLD and&#xD;
      advanced fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, prospective, observational cohort study. We plan to include&#xD;
      10,000 patients with type 2 diabetes, and use FibroTouch to screen for NAFLD, NASH cirrhosis&#xD;
      and advanced fibrosis in these patients. In the group of patients who experienced liver&#xD;
      biopsies in clinical practice, we compare their FibroTouch results and liver biopsy pathology&#xD;
      results, to evaluate the clinical value of FibroTouch in diagnosing NAFLD, NASH cirrhosis and&#xD;
      advanced fibrosis in diabetics. We will calculate the incidence and analyze risk factors of&#xD;
      NAFLD, NASH cirrhosis and advanced fibrosis in patients with type 2 diabetes. All patients&#xD;
      will be followed-up for 5 years (once a year for patients without cirrhosis, twice a year for&#xD;
      patients with cirrhosis), to observed endpoint events. This study will explore the&#xD;
      significance of FibroTouch result and other clinical indicators in assessing the long-term&#xD;
      prognosis of diabetic patients with NAFLD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 5, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>5 years</time_frame>
    <description>Noticed death of patient at follow-up visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver steatosis</measure>
    <time_frame>5 years</time_frame>
    <description>Liver steatosis detected by FibroTouch, or liver biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Advanced fibrosis, compensated cirrhosis, decompensated cirrhosis</measure>
    <time_frame>5 years</time_frame>
    <description>Advanced fibrosis, compensated cirrhosis, decompensated cirrhosis detected by FibroTouch, ultrasound, CT, MRI or liver biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatocellular carcinom</measure>
    <time_frame>5 years</time_frame>
    <description>Hepatocellular carcinoma detected by CT, MRI or liver biopsy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cardiovascular and cerebrovascular diseases</measure>
    <time_frame>5 years</time_frame>
    <description>Diagnosed by cardiologists or neurologist</description>
  </other_outcome>
  <other_outcome>
    <measure>Extrahepatic tumors</measure>
    <time_frame>5 years</time_frame>
    <description>Diagnosed by oncologists</description>
  </other_outcome>
  <other_outcome>
    <measure>Chronic kidney disease</measure>
    <time_frame>5 years</time_frame>
    <description>Diagnosed by nephrologists</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Nonalcoholic Fatty Liver Disease (NAFLD)</condition>
  <arm_group>
    <arm_group_label>Type 2 Diabetes Mellitus</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FibroTouch</intervention_name>
    <description>FibroTouch is a non-invasive image-guided integrated detection system, providing an integrated detection and comprehensive evaluation program for hepatic fibrosis and hepatic steatosis.&#xD;
The FibroTouch is a completely non-invasive liver testing device that can obtain the following results: 1. Liver Fibrosis: quantitative results of hepatic fibrosis; 2. Fatness: quantitative result of hepatic steatosis; 3. Liver tissue morphology: detected by ultrasound imaging.</description>
    <arm_group_label>Type 2 Diabetes Mellitus</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      5mL peripheral blood placed in sodium citrate vacuum tube, 5mL peripheral blood serum, and&#xD;
      10mL random urine are collected at the baseline information and specimen collection. 10mL&#xD;
      random urine is collected at each time follow-up. All these samples are used for screening&#xD;
      potential indicators to evaluate prognosis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study include 10000 type 2 diabetes patients (both inpatients and outpatients of these&#xD;
        cooperative member hospitals). We exclude the patients with other type of diabetes, other&#xD;
        liver diseases, pregnancy or breastfeeding,malignancy, using the drugs that would possibly&#xD;
        cause secondary diabetes or fatty liver.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diagnosed as type 2 diabetes mellitus(fulfill at least one of the followings):&#xD;
&#xD;
          1. Random plasma glucose levels ≥11.1 mmol/L (twice or more on different days, or once&#xD;
             with typical symptoms of diabetes);&#xD;
&#xD;
          2. Fasting plasma glucose levels ≥ 7.0 mmol/L (twice or more on different days, or once&#xD;
             with typical symptoms of diabetes);&#xD;
&#xD;
          3. 2h plasma glucose level ≥11.1 mmol/L(twice or more on different days, or once with&#xD;
             typical symptoms of diabetes);&#xD;
&#xD;
          4. Previously diagnosed as type 2 diabetes mellitus, plasma glucose level is normal under&#xD;
             the current diabetes treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes or other types of diabetes;&#xD;
&#xD;
          -  Acute or chronic infection;&#xD;
&#xD;
          -  Other diseases that cause secondary diabetes: such as pancreatic disease, Cushing's&#xD;
             syndrome, acromegaly, glucagonoma, pheochromocytoma, hyperthyroidism, somatostatin,&#xD;
             aldosteronoma, etc.;&#xD;
&#xD;
          -  Using drugs that cause secondary diabetes (glucocorticoid, thyroid hormone, phenytoin,&#xD;
             alpha-interferon, etc.)&#xD;
&#xD;
          -  Hepatitis B surface antigen positive (HBsAg+), or hepatitis C antibody positive&#xD;
             (Anti-HCV+), or other liver diseases such as alcoholic liver disease;&#xD;
&#xD;
          -  Alcohol intake ≥140g/week for men (or ≥70 g/week for women);&#xD;
&#xD;
          -  Diagnosed with HCC or other malignancy (in accordance with the appropriate diagnostic&#xD;
             criteria);&#xD;
&#xD;
          -  Drugs secondary to fatty liver (tamoxifen, amiodarone, valproate, methotrexate,&#xD;
             glucocorticoids, etc.).&#xD;
&#xD;
          -  During pregnancy or breastfeeding;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinjun Chen</last_name>
    <phone>8618588531001</phone>
    <email>chjj@smu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yali Ji</last_name>
    <phone>8615210580706</phone>
    <email>jiyl09@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinjun Chen</last_name>
      <phone>86-18588531001</phone>
      <email>chjj@smu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yali Ji</last_name>
      <phone>8615210580706</phone>
      <email>jiyl09@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

